# Peter Kolkhof

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/peter-kolkhof/

## Facts

| Field | Value |
| --- | --- |
| Citations | 14,768 |
| Field | Hormonal Regulation and Hypertension |
| h-index | 52 |
| i10-index | 92 |
| Last Known Institution | Bayer (United States) |
| OpenAlex ID | https://openalex.org/A5050612283 |
| ORCID iD | 0000-0003-3425-7528 |
| Works | 176 |

## Researcher papers

- [Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes](https://scholariq.org/papers/effect-of-finerenone-on-chronic-kidney-disease-outcomes-in-type-2-diabetes/)
- [Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis](https://scholariq.org/papers/cardiovascular-and-kidney-outcomes-with-finerenone-in-patients-with-type-2/)
- [Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/finerenone-in-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/)
- [Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy](https://scholariq.org/papers/effect-of-finerenone-on-albuminuria-in-patients-with-diabetic-nephropathy/)
- [Molecular mechanisms and therapeutic targets for diabetic kidney disease](https://scholariq.org/papers/molecular-mechanisms-and-therapeutic-targets-for-diabetic-kidney-disease/)
- [Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine](https://scholariq.org/papers/steroidal-and-non-steroidal-mineralocorticoid-receptor-antagonists-in/)
- [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial](https://scholariq.org/papers/safety-and-tolerability-of-the-novel-non-steroidal-mineralocorticoid-receptor/)
- [A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease](https://scholariq.org/papers/a-randomized-controlled-study-of-finerenone-vs-eplerenone-in-patients-with/)
- [Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury](https://scholariq.org/papers/finerenone-a-novel-selective-nonsteroidal-mineralocorticoid-receptor-antagonist/)
- [Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes](https://scholariq.org/papers/finerenone-and-cardiovascular-outcomes-in-patients-with-chronic-kidney-disease/)
- [A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease](https://scholariq.org/papers/a-randomized-controlled-study-of-finerenone-vs-eplerenone-in-japanese-patients/)

## Researcher topics

- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)
- [Ion Transport and Channel Regulation](https://scholariq.org/topics/ion-transport-and-channel-regulation/)
- [Electrolyte and hormonal disorders](https://scholariq.org/topics/electrolyte-and-hormonal-disorders/)
- [Adrenal Hormones and Disorders](https://scholariq.org/topics/adrenal-hormones-and-disorders/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)

## Researcher university

- [Bayer (United States)](https://scholariq.org/institutions/bayer-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.